Dung Le, MD

Professional Titles

• Bloomberg~Kimmel Professor of Cancer Immunotherapy

Primary Academic Title

Professor of Oncology

Background

Centers and Institutes

• Sidney Kimmel Comprehensive Cancer Center
• Skip Viragh Center for Pancreatic Cancer

Videos

• Beating Cancer: Precision Immunotherapy

PubMed

http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/46169577/?sort=date&direction=ascending

Selected Publications

• Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Jr., Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858-868. PMCID: PMC3289408. Role: Lead investigator on multi-institutional study. Designed and conducted the study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Received an ASCO Career Development Award to conduct this study. 

• Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM. CD8(+) Foxp3(+) tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Internat J Cancer. Journal international du cancer. 2011;129(3):636-647. PMCID: PMC3064958. Role: Designed and performed the experiments. Conducted data analysis. Primary author on manuscript.

• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunotherapy. 2013;36(7):382-389. PMCID: PMC3779664. Role: Principal investigator study. Designed and conducted the study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Wrote R21 that funded this study (R21CA126058-01A2).

• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Le JJ, Duffy SM, Goldberg RM, de la Chappelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch repair deficiency. NEJM. 2015. PMCID: PMC4481136; Role: Lead investigator on multi-institutional study. Designed and conducted study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Received a GI SPORE grant to conduct microsatellite instability testing (MSI) for prescreening component of study (P50 CA62924).

• Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Jan 12. PMCID: PMC4397277; Role: Lead investigator on multi-institutional study. Designed and conducted the study. Conducted analysis of both clinical and correlative studies and was primary author on manuscript. Funding: Received a K23, Career Development Award to conduct this study. 1K23CA163672